Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma

August 2nd 2012

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.

Researchers Share Honor for Bortezomib Discovery

July 27th 2012

Bortezomib represented a major discovery in cancer research and has helped some patients achieve a complete pathological response and live longer.

FDA Approves Carfilzomib for Relapsed Multiple Myeloma

July 23rd 2012

The FDA approved carfilzomib for patients with multiple myeloma who have received at least two prior lines of therapy.

Hematology Pipeline: Baby Steps After a Giant Leap

June 21st 2012

A closer look at the hematology pipeline where there are multiple promising studies in progress for hematologic malignancies, including lymphoma, leukemia, and multiple myeloma.

ODAC Supports Carfilzomib for Relapsed Multiple Myeloma

June 20th 2012

ODAC voted 11-0 in support of carfilzomib as a new treatment option for patients with multiple myeloma, despite side effect concerns raised by the FDA.

Michael Eckenfels on Bortezomib Delivery Route Changes

May 5th 2012

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

Elotuzumab Responses High in Multiple Myeloma Study

April 12th 2012

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma

March 23rd 2012

Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.

Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

March 20th 2012

Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.

Dr. Jagannath Discusses the VANTAGE Trials

March 12th 2012

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

Investigational Treatments for Multiple Myeloma

March 5th 2012

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

Dr. Jagannath on HDAC Inhibitors for Multiple Myeloma

February 29th 2012

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma

Current Trends in the Treatment of Newly Diagnosed Myeloma

February 24th 2012

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

Dr. Berenson on Zometa as the Gold Standard for Myeloma

February 9th 2012

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Novel Therapeutics Have Revolutionized Multiple Myeloma Treatment

February 2nd 2012

Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.

Bortezomib Approved for Subcutaneous Injection

January 24th 2012

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.

Update on Bone Disease in Multiple Myeloma

December 19th 2011

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Refining Maintenance Therapy for Multiple Myeloma

November 21st 2011

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.

Dr. Berenson Discusses the Carfilzomib Toxicity Profile

November 18th 2011

Dr. James Berenson from the Institute for Myeloma & Bone Cancer Research Discusses the Carfilzomib Toxicity Profile

Novel Drugs and Combinations Promise to Improve Outcomes for Patients With Myeloma

November 14th 2011

Current treatments revolutionized multiple myeloma but combinations and novel approaches in development promise to make even greater strides in treating this disease.